XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Summary of Financial Information with Respect to Reportable Segments
Presented below is financial information with respect to the Company’s reportable segments for the periods presented:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Segment revenues:
Software$31,884 $28,904 $100,703 $90,469 
Drug discovery3,406 13,665 18,519 52,071 
Total segment revenues$35,290 $42,569 $119,222 $142,540 
Segment gross profit:    
Software$23,405 $21,870 $77,081 $69,625 
Drug discovery(5,677)1,769 (9,128)13,517 
Total segment gross profit17,728 23,639 67,953 83,142 
Unallocated:    
Research and development(50,977)(46,833)(152,423)(130,279)
Sales and marketing(10,349)(9,109)(30,213)(27,276)
General and administrative(24,824)(23,890)(73,901)(73,414)
Gain on equity investments— — — 147,322 
Change in fair value25,459 (14,522)27,763 61,869 
Other income4,737 5,804 14,363 13,067 
Income tax benefit (expense)90 2,887 (449)(3,041)
Consolidated net (loss) income$(38,136)$(62,024)$(146,907)$71,390 
Schedule of Revenues by Geographic Area The following table sets forth revenues by geographic area for the three and nine months ended September 30, 2024 and 2023:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$24,622 $33,127 $78,617 $107,435 
APAC5,280 5,567 19,490 18,877 
EMEA5,145 3,758 20,147 15,418 
Rest of World243 117 968 810 
$35,290 $42,569 $119,222 $142,540